Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Prostate Cancer

 

Immune Monitoring of Sipuleucel-T
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Investigator: Celestia S. Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01727154

Phenelzine Sulfate and Docetaxel Post First-Line Docetaxel Therapy
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01253642

Abiraterone Acetate for Metastatic, Castration Resistant Prostate Cancer
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01508234

Abiraterone Acetate for Metastatic Hormone-Resistant Prostate Cancer (7639)
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01503229

OGX-011 for Metastatic Castrate Resistant Prostate Cancer (SYNERGY)
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer

Investigator: Celestia S. Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01188187

GTx-758 for Castration Resistant Prostate Cancer
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01615120

DSTP3086S for Metastatic Castration-Resistant Prostate Cancer (20121064)
A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP30862 in Patients with Metastatic Castration-Resistant Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer; Solid Tumors;    Status: Open;   Study ID: NCT01283373

Radiation Therapy vs. Androgen Deprivation
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy (RTOG 0534)

Investigator: George Laramore, MD, PhD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT00567580

Degarelix Acetate Prior to Radiation Therapy (7846)
Degarelix Acetate Prior to Radiation Therapy

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01731912

Molecular correlates of sensitivity and resistance to therapy in prostate cancer (UW6932)
Molecular correlates of sensitivity and resistance to therapy in prostate cancer

Investigator: Robert Montgomery, MD;   Conditions: Metastatic Prostate Cancer;    Status: Recruiting;   Study ID: NCT01050504

PASS
Canary Prostate Active Surveillance Study

Investigator: Daniel W. Lin, MD;   Conditions: Prostatic Neoplasms;    Status: Recruiting;   Study ID: NCT00756665

ARN-509 for Relapsed Hormone Sensitive Prostate Cancer (20130917)
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01790126

Biological Therapy w/wo Vaccine Therapy for Metastatic Hormone-Resistant Prostate Cancer (8037A)
A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Pending;   Study ID: NCT01881867

PET Imaging as a Biomarker of Treatment Response for Prostate Cancer (8021)
PET Imaging as a Biomarker of Systemic Treatment Response for Men with Metastatic Castration-Resistant Prostate Cancer

Investigator: Evan Yu, MD;   Conditions: Genitourinary Cancer; Prostate Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT02169063

AZD8186 Ascending Dose Study
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours

Investigator: Celestia S. Higano, MD;   Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);, Squamous Non-Small Cell Lung Cancer (sqNSCLC);, Triple Negative Breast Cancer (TNBC);    Status: Recruiting;   Study ID: NCT01884285

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Enzalutamide for Castrate-resistant Prostate Cancer
Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing

Investigator: ;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01942837

ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (SWOG 1216)
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Investigator: Heather H. Cheng, MD, PhD;   Conditions: Prostate Cancer;    Status: Pending;   Study ID: NCT01809691

Seizure Risk Evaluation of Patients Treated with Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure

Investigator: ;   Conditions: Metastatic Castration- Resistant Prostate Cancer (mCRPC);    Status: Recruiting;   Study ID: NCT01977651